he following is provided by Navellier with technical comment from South Ocean Management – pls do your own due diligence.
(For this 2020 year, SOM will track only the Top 5 Hi-Growth Investments.)

https://navelliergrowth.investorplace.com/

Navellier says,

High-Growth Investments

DocuSign, Inc.

DocuSign, Inc. (DOCU) is one of the hottest stocks in the Growth Investor Buy Lists, as the stock has climbed an impressive 60% in the past four months. The reality is that the company has fared well during the global pandemic given that many folks are afraid to sign documents; whether it’s a reluctance to visit an office or the potential for germs on pens.

As a result, many have turned to DocuSign to utilize their e-signature technologies. You may recall that DocuSign offers a cloud-based platform that enables businesses and individuals to develop, upload, sign and send agreements and documents virtually. And its technology can be integrated with several solutions, including Salesforce and Workday.

So, it’s not surprising that DocuSign posted incredible results for its second quarter in fiscal year 2021. The company reported total revenue of $342.2 million and earnings of $0.17 per share, which represented 45% annual revenue growth and 1,600% annual earnings growth. Analysts were expecting earnings of $0.08 per share, so DocuSign posted a whopping 112.5% earnings surprise.

Following the better-than-expected earnings report, analysts started to up their third-quarter earnings outlook. Earnings are now expected to grow 18.2% year-over-year to $0.13 per share, and revenue is forecast to rise 44.6% year-over-year to $360.87 million. DOCU is a Moderately Aggressive buy below $235.

SOM Technicals:

6-26-20: Closed at 177.58. Trade pressures are up. Volumes are bullish. This spike up is not likely to continue in the face of the sell off.

7-4-20: Closed at 190.99. Trade pressures are up. Volumes are bullish. This parabolic move is very uncomfortable.

7-10-20: Closed at 210.11. Trade pressures are up but reversing. A close below 210 would signal lower.

7-18-20: Closed at 196.42. Trade pressures are down but rising. Volumes are neutral. The next target up is 217.

7-24-20: Closed at 190.95. Trade pressures are down. Volumes are bearish. The next target down is 172.23.

7-30-20: Closed at 217.45. Trade pressures are up. Volumes are bullish. The next target up is 257.20.

8-7-20: Closed at 205.00. Trade pressures are down. Volumes are bearish. Dropped thru two downside targets this week. The next target down is 185.06.

8-15-20: Closed at 199.71. Trade pressures are neutral. Volumes are neutral also. Traded down near the 185.06 target and now has moved higher. At the 25×5 MA and looks lower. The next target don is the 185.91 Target.

8-21-20: Closed at 210.18. Trade pressures are up but showing reversal. Volumes are bullish. The next target up is 221.00.

8-29-20: Closed at 215.24. Trade pressures are up. Volumes are bearish. resistance here at the 217.23 level, which is also the new long entry.

9-5-20: Closed at 216.26: Trade pressures are down. Volumes are bearish. Sitting on the 25×5 MA support at 216.

9-12-20: Closed at 197.94. Trade pressures are down. Volumes are bearish. A close below 196.53 triggers a new short entry.

9-19-20: Closed at 194.42. Trade pressures are down. Volumes are neutral. The next target down is 173.35.

9-26-20: Closed at 212.36. Trade pressures are down into the neutral zone. Volumes are bullish. The next target down is 173.35.

10-11-20: Closed at 225.80. Trade pressures are down into the neutral zone. Volumes are bullish. A close above 240 would signal higher.

10-17-20: Closed at 234.60. Trade pressure are up. Volume are bullish. The next target up is 300.00.

10-24-20: Closed at 219.82. Trade pressures are down but reversing. Volumes are bearish. The next target down is 195.29.

 

Genmab A/S

Genmab A/S (GMAB) is a biotechnology company that’s focused on developing antibody therapeutics to treat cancer. Currently, Genmab has two products on the market: DARZALEX, or Daratumumab, to treat multiple myeloma and Arzerra, or Ofatumumab, to treat specific indications of chronic lymphocytic leukemia.

Recently, Janssen Biotech, Inc. submitted a supplemental Biologics License Application (sBLA) for Genmab’s DARZALEX FASPRO with the FDA. The application will be reviewed by the FDA under Project Orbis and RTOR pilot program to determine if the treatment is a viable option for adults with light-chain (AL) amyloidosis. With the submission of the sBLA, Genmab receives an $8 million milestone payment.

Thanks to rising demand for its antibody therapeutics, vast clinical pipeline and strategic partnership with AbbVie, Genmab has strong forecasted sales growth and earnings estimates have been revised higher over the past three months. Third-quarter sales are expected to soar 55.8% year-over-year to $241.41 million. Earnings per share estimates have been upped 91.7% in the past three months, which bodes well for a third-straight quarterly earnings surprise. GMAB is a Conservative buy below $39.

SOM Technicals:

9-26-20: Closed at 36.02. Trade pressures are down but rising. Volumes are neutral. The next target down is 33.20.

10-11-20: closed at 37.46. Trade pressures are up. V olumes are neutral. Trade down to the 34.28 down side target then rallied. Still in the down trend but a close above 38.52 changes to uptrend.

10-17-20: Closed at 36.79. Trade pressures are down but reversing. Volumes are neutral. At supprort.

10-24-20: Closed at 35.67. Trade pressures are down and basing. Volumes are bullish. The next target down is 34.28.

 

Novavax, Inc.

Novavax, Inc. (NVAX) was one of our September additions to the High-Growth Investments Buy List. If you recall, the company develops vaccines for the toughest viruses in the world. Novavax currently has a strong pipeline of vaccine candidates, including several that are in Phase 2 and 3 clinical trials. But its coronavirus vaccine candidate is one of the main reasons why we added the stock to the Buy List.

Novavax’s vaccine candidate is being funded by both the federal government through Operation Warp Speed and the Bill & Melinda Gates Foundation. Thanks to positive Phase 1 results, the company has started multiple Phase 2 clinical trials, including in the U.S. and Australia. And Canada recently announced that it will purchase up to 76 million doses of Novavax’s vaccine.

Given the success of its early clinical trials and countries knocking on its door for the approved vaccine, the analyst community has aggressively increased their third-quarter earnings outlook. Analysts are expecting earnings of $1.83 per share, up from previous estimates for an earnings per share loss of $0.10. As you know, positive earnings revisions typically precede future earnings surprises. NVAX is an Aggressive buy below $181.

SOM Technicals:

9-26-20: Closed at 113.56. Trade pressures are up. Volumes are bullish. The next target up is 129.69.

10-11-20: Closed at 111.12. Trade pressures are up and trending. Volumes are buillish. The next target up is 129.00. 

10-17-20: Closed at 107.04. Trade pressures are down. volumes are bearish. A close below 101 would signal lower.

10-24-20: Closed at 93.13. Trade pressures are down and trending. Volumes are bullish. the next target down is 73.45.

 

Quidel Corporation

With more primary schools and universities opening their doors, the need for coronavirus testing kits is growing exponentially. In fact, my daughter attends Cornell University, and they continually check her for the virus (negative results each time). One of the biggest beneficiaries of all the coronavirus testing is our own Quidel Corporation (QDEL), which developed the SARS-CoV-2 test for COVID-19.

According to a recent article from Reuters, U.S. manufacturers are ramping up production on COVID-19 tests, looking to achieve 100 million test each month by the end of year. Quidel, along with Abbott Labs, Becton Dickinson & Co. and LumiraDX, all received authorization for their antigen tests. Quidel actually received an emergency use authorization (EUA) from the FDA for its SARS-CoV-2 test earlier this year.

As a result, analysts are anticipating blowout third-quarter results. The consensus estimate calls for earnings of $4.06 per share, or 480% annual earnings growth, and revenue of $394.28 million. Analysts have also increased earnings by an incredible 80.4% in the past three months, so a fifth-straight quarterly earnings surprise is likely. QDEL is an Aggressive buy below $237.

SOM Technicals:

7-30-20: Closed at 282.47. Trade pressures are up. Volumes are bullish. The next target up is 367.57.

8-7-20: Closed at 272.76. Trade pressures are down. Volumes are bearish. The next target down is 259.83 the 25×5 MA.

8-15-20: Closed at 245.93. Trade pressures are up. Volumes are bearish. At the 25×5 MA. Should act as resistance. The next target down is 215.00.

8-21-20: Closed at 241.52. Trade pressures are in the neutral zone. Volume are bearish. Appears to want to test the 200.00 support level.

8-29-20: Closed at 162.97. Trade pressures are down hard. Volumes are neutral, short covering? The 200 day MA held as support. A close above 188.83 is the new long entry.

9-5-20: Closed at 154.41. Trade pressures are down. Volumes are bearish. 200 day MA is holding as support.

9-12-20: Closed at 161.19. Trade pressures are rising into the neutral zone. Volumes are now bullish. A close above 188.63 would signal higher.

9-19-20: Closed at 188.50. Trade pressures are up. Volumes are bullish. Has triggered a new long entry. The next target up is 248.00.

9-26-20: Closed at 196.77. Trade pressures are up but turning down. Volumes are bullish. The next target down is 161.41.

10-11-20: Closed at 278.05. (Nice  move while i was gone!) Trade pressures are up and trending. Volumes are bullish. The next target up is 290.43.

10-17-20: Closed at 255.25. Trade pressures are down. Volumes are bearish. A retest of the breakout. support at 223.

10-14-20: Closed at 248.21. Trade pressures are down and trending. Volumes are bearish. At the 239 support.

 

Zoom Video Communications, Inc.

Zoom Video Communications, Inc. (ZM) has certainly been one of the biggest beneficiaries of the global pandemic, as its online video and audio conference call platform has been a primary tool for companies to continue to do business. In fact, ZM shares defied broader market weakness earlier this week when the U.K. imposed a new round of restrictions and encouraged citizens to work from home. ZM shares are up more than 65% in the past four weeks alone, versus the S&P 500’s 6% decline.

Part of this strength came on the heels of a stunning second-quarter earnings reports. For its second quarter in fiscal year 2021, Zoom achieved revenue of $663.5 million and earnings of $274.8 million, or $0.92 per share, which represented 355% annual revenue growth and 1,045% annual earnings growth. The consensus estimate called for earnings of $0.45 per share, so Zoom posted an incredible 104.4% earnings surprise.

Looking forward, I expect Zoom to continue to outperform the broader market and its peers, as demand remains strong for its platform for the foreseeable future. And I’m not alone. The analyst community has increased third-quarter earnings estimates by 123.5% in the past three months. For its third quarter in fiscal year 2021, earnings are expected to surge 744% year-over-year to $0.76 per share and revenue is forecast to soar 315.4% year-over-year to $692.05 million. ZM is an Aggressive buy below $601.

SOM Technicals:

7-30-20: Closed at 253.91. Trade pressures are down but rising into the neutral zone. Volumes are bearish. The next target down is 209.79.

8-7-20: Closed at 258.73. Trade pressures are down. Volumes are Bearish. The next target down is 239.12.

8-15-20: Closed at 244.91. Trade pressures are up. Volumes are bearish. Rising into net bearish volumes after reaching the 227.53. target. Need to get thru the 25×5 MA at 254.63, otherwise more downside.

8-21-20: Closed at 289.68. Trade pressures are up and trending. Volumes are bullish. The resistance was non- existent. A new long entry was triggered at 271.00.

8-29-20: Closed at 299.27. Trade pressures are up. Volumes are bullish. The next target up is 314.82.

9-5-20: Closed at 369.89. Trade pressures are down into the neutral zone. Volumes are bullish. The next target down is 314.78 which would close the gap up. 

9-12-20: Closed at 383.00. Trade pressures are now up. Volumes are bearish. A close below 376 would signal a new leg down.

9-19-20: Closed at 438.73. Trade pressures are up. Volumes are bullish. In the new move after a back test to try to close the gap a t 345. The next target up is 470.76.

9-26-20: Closed at 496.50. Trade pressures are up but declining. Volumes are now neutral. The next target down is 452.23.

10-11-20: Closed at 492.41. Trade pressures up Volumes are bullish. The next target up is the 529.74  prior high.

10-17-20: Closed at 559.00. Trade pressures are up and trending. Volumes are bullish. the next target up is 594.76.

10-24-20: Closed at 511.52. Trade pressures are down. Volumes are bearish. The next target down is 487.96.